Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

Explore strategies for controlling COPD and improving health, with a focus on management and lifestyle changes.

China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on 24 January ...

Authenticated data presented in the Respiratory Drugs market report is based on findings of extensive primary and secondary research ...

Certain Medicare plans typically cover at least part of the cost of inhalers for COPD. There are also several ways to further save on costs.

Objectives To establish, within people with COPD, (1) whether ICS reduced MACE rates (acute coronary syndrome (ACS), heart failure (HF), ischaemic strokes or cardiovascular-specific death) compared ...

The announcement that inhaled insulin will soon be available in India has understandably generated a lot of excitement and ...

Patients with COPD had slightly more major adverse cardiovascular events after initiating single-inhaler triple therapy vs a LABA-ICS inhaler.

Black Americans have a higher likelihood of having asthma-COPD overlap syndrome (ACOS) but may not know it. Here’s what you ...

Windward’s lead candidate, WIN378, is a recombinant, fully human monoclonal antibody with long-acting properties that can potentially ... such as boosting inflammation in asthma and COPD. WIN378 is ...

Headquartered in Switzerland, Windward Bio is a clinical-stage drug development company ... windward-bio-launch-to-advance-long-acting-treatments-for-asthma-and-copd-302348011.html Biotechnologie ...